ClinicalTrials.gg
CompletedNCT05227690Updated Sep 17, 2025Results posted

A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

A Phase 2 interventional study of Placebo and Emraclidine 10 mg in Schizophrenia, sponsored by AbbVie. Completed at 25 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
385
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Schizophrenia by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Schizophrenia · AbbVie.

Enrollment
10th of 27
385 · median 268
Started
2022
with 4 others
Phase 2
13 of 27
1 open now
Registered
22nd of 27
by date

Among the 27 studies in Schizophrenia by AbbVie, this one is the 10th largest by enrollment, is one of 5 that started in 2022, is one of 13 in phase 2, and was the 22nd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 27 studies in Schizophrenia by AbbVie is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Schizophrenia by AbbVie, or all of them as a file.
02

Study summary

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (10 mg QD and 30 mg QD) in male and female participants who have schizophrenia and are experiencing an acute exacerbation of psychosis.

03

Conditions studied

  • Schizophrenia

Keywords

  • Schizophrenia
  • Schizophrenia Spectrum and Other Psychotic Disorders
  • Mental Disorders
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary diagnosis of schizophrenia per , as confirmed by the MINI for Psychotic Disorders.
  • CGI-S ≥4 (moderately to severely ill) at the time of signing the ICF and Baseline.
  • PANSS Total Score between 85 and 120, inclusive, at the time of signing the ICF and at Baseline.
  • Experiencing an acute exacerbation or relapse of psychotic symptoms, with onset less than 60 days prior to signing the ICF.
  • Willing to discontinue all prohibited medications to meet protocol-required washouts prior to and during the trial period.
  • of 18.0 to 40.0 kg/m2 and a total body weight ≥50 kg (110 lbs).
  • Ability, in the opinion of the investigator, to understand the nature of the trial, participate in trial visits, and comply with protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis other than schizophrenia (note: anxiety symptoms secondary to schizophrenia are allowed); Acute depressive symptoms within 30 days prior to signing the ICF that require treatment with an antidepressant are exclusory. Acute manic symptoms within 30 days prior to signing the ICF that require treatment with a mood stabilizer are exclusory.
  • Any of the following:

    • Schizophrenia considered resistant/ to antipsychotic treatment by history (failure to respond to 2 or more courses of adequate pharmacological treatment defined as an adequate dose per label and a treatment duration of at least 4 weeks)
    • History of response to clozapine treatment only or failure to respond to clozapine treatment
  • Any of the following regarding history of schizophrenia:

    • Time from initial onset of schizophrenia \<2 years based on prior records or participant self-report
    • Presenting with an initial diagnosis of schizophrenia
    • Presenting for the first time with an acute psychotic episode requiring treatment
  • Reduction (improvement) in PANSS total score of ≥20% between Screening and Baseline.
  • Current or past history of significant cardiovascular, pulmonary, gastrointestinal, renal, hepatic, metabolic, genitourinary, endocrine (including diabetes mellitus), (except for basal cell carcinoma of the skin and cervical carcinoma in situ, at the discretion of the investigator), hematological, immunological, neurological, or psychiatric disease that, in the opinion of the investigator or medical monitor, could compromise either participant safety or the results of the trial.
  • Active central nervous system infection, demyelinating disease, degenerative neurological disease, brain tumor, prior hospitalization for severe head trauma, seizures (excluding febrile seizures in childhood), or any central nervous system disease deemed to be progressive during the course of the trial that may confound the interpretation of the trial results
  • Diagnosis of moderate to severe substance or alcohol-use disorder (excluding nicotine or caffeine) as per DSM-5 criteria within 12 months prior to signing the ICF.
  • Risk for suicidal behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) and investigator's clinical assessment.
  • Any condition that could possibly affect drug absorption.
  • Use of prohibited medications prior to randomization within the required or likely to require prohibited concomitant therapy during the trial.
  • abnormal findings on the physical examination, medical history review, , or clinical laboratory results at screening.
  • Positive pregnancy test result prior to receiving IMP. Note: female participants who are pregnant, breastfeeding, or planning to become pregnant during IMP treatment or within 7 days after the last dose of IMP are also excluded.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
385 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo tablets orally once daily (QD) through Day 45 of Week 6.

    Drug: Placebo

  • Experimental
    Emraclidine 10 mg, once daily (QD)

    Participants received emraclidine 10 mg tablets orally once daily (QD) through Day 45 of Week 6.

    Drug: Emraclidine 10 mg

  • Experimental
    Emraclidine 30 mg, once daily (QD)

    Participants received emraclidine 30 mg tablets orally once daily (QD) through Day 45 of Week 6.

    Drug: Emraclidine 30 mg

Interventions

  • DrugPlacebo

    Matching placebo, oral (tablet), once per day for 6 weeks

  • Emraclidine 10 mg, oral (tablet), once per day for 6 weeks

    Also known as: CVL-231, ABBV-1231

  • Emraclidine 30 mg, oral (tablet), once per day for 6 weeks

    Also known as: CVL-231, ABBV-1231

06

What researchers measure

Primary outcomes

  1. Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score

    The PANSS measures symptom severity of participants with schizophrenia and contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale with a total minimum score of 30 and a maximum score of 210. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.

    Time frame: Baseline through Week 6

Secondary outcomes

  1. Change From Baseline at Week 6 in the Clinical Global Impression - Severity (CGI-S Score)

    The CGI-S captures clinician's response to: "Considering your total clinical experience, how mentally ill is the participant at this time?" The clinician's answer was based on the following scale: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. Negative changes from Baseline indicate less mental illness.

    Time frame: Baseline through Week 6

  2. Change From Baseline at All Time Points in Positive and Negative Syndrome Scale (PANSS) Total Score

    The PANSS measures symptom severity of participants with schizophrenia and contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale with a total minimum score of 30 and a maximum score of 210. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.

    Time frame: Baseline; Weeks 1, 2, 3, 4, 5, and 6

  3. Change From Baseline at All Time Points in the Clinical Global Impression - Severity (CGI-S) Score

    The CGI-S captures clinician's response to: "Considering your total clinical experience, how mentally ill is the participant at this time?" The clinician's answer was based on the following scale: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. Negative changes from Baseline indicate less mental illness.

    Time frame: Baseline; Weeks 1, 2, 3, 4, 5, and 6

  4. Percentage of Responders at Week 6 (Responders Defined as ≥30% Reduction From Baseline in Positive and Negative Syndrome Scale [PANSS] Total Score)

    The PANSS measures symptom severity of participants with schizophrenia and contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale with a total minimum score of 30 and a maximum score of 210. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms. A PANSS responder is defined as a participant with at least a 30% decrease in PANSS total score compared to Baseline at Week 6 visit or the early termination visit. If a participant discontinued and did not have an early termination visit, the participant's last assessment was considered.

    Time frame: Baseline through Week 6

  5. Number of Participants With Treatment Emergent Adverse Event (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

    Time frame: From first dose of study drug until 28 days following last dose of study drug (up to Week 10)

  6. Number of Participants With Clinically Significant Changes in Electrocardiogram (ECGs)

    12-lead electrocardiogram (ECG) recordings were obtained after the participant had been supine and at rest for at least 3 minutes.

    Time frame: Baseline; from first dose of study drug up to Week 6

  7. Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments

    Clinical laboratory tests were performed at scheduled study visits, and the investigator recorded any clinically significant changes.

    Time frame: Baseline; from first dose of study drug up to Week 6

  8. Number of Participants With Clinically Significant Changes in Vital Sign Measurements

    Vital signs were obtained after the participant had been supine and at rest for 3 minutes and included temperature, systolic and diastolic blood pressure, respiratory rate, and heart rate. Participants' body weights were also measured and recorded.

    Time frame: Baseline; from first dose of study drug up to Week 6

  9. Number of Participants With Clinically Significant Changes in Physical and Neurological Examination Results

    The number of participants with clinically significant changes in physical and neurological examination results was documented.

    Time frame: Baseline; from first dose of study drug up to Week 6

  10. Number of Participants With Suicide-Related Treatment-Emergent Events Assessed Using the Columbia Suicide-Severity Rating Scale (C-SSRS)

    The C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent).

    Time frame: Baseline; from first dose of study drug up to Week 6

  11. Change From Baseline in Simpson Angus Scale (SAS) Total Score

    The SAS consists of a list of 10 symptoms of Parkinsonism. Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms and a score of 4 representing a severe condition. The SAS total score is the sum of the scores for all 10 items. Negative changes from Baseline indicate an improvement in symptoms.

    Time frame: Baseline; Weeks 3 and 6

  12. Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Movement Rating Score

    The Abnormal Involuntary Movement Scale assessment consists of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1-4), extremity movements (items 5 and 6), and trunk movements (item 7) are observed unobtrusively while the participant is at rest, and the investigator also makes global judgments on the participant's dyskinesias (items 8-10). Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms (for item 10, no awareness), and a score of 4 indicating a severe condition (for item 10, awareness, severe distress). In addition, the AIMS includes 2 yes/no questions that address the participant's dental status. The AIMS Movement Rating Score is defined as the sum of individual scores from items 1-7, ranging from 0 to 28. A lower score indicates less severe or absent abnormal movements. A negative change in the mean from Baseline indicates improvement in the severity of abnormal involuntary movements.

    Time frame: Baseline; Weeks 3 and 6

  13. Change From Baseline in Barnes Akathisia Rating Scale (BARS) Global Clinical Evaluation Score

    The BARS consists of 4 items related to akathisia: The first 3 items are rated on a 4-point scale, with a score of 0 representing absence of symptoms and a score of 3 representing a severe condition. The global clinical evaluation is made on a 6-point scale, with a score of 0 representing absence of symptom and a score of 5 representing severe akathisia. Negative changes from Baseline indicate an improvement in symptoms.

    Time frame: Baseline; Weeks 3 and 6

07

Results

Posted Sep 17, 2025

Participant flow

This trial was conducted at 23 sites in the United States and Bulgaria.

Participant flow — Overall Study
MilestonePlaceboEmraclidine 10 mg, Once Daily (QD)Emraclidine 30 mg, Once Daily (QD)
Started128128129
Completed858992
Not completed433937
Withdrew: Adverse event5610
Withdrew: Lack of efficacy241
Withdrew: Physician decision604
Withdrew: Withdrawal of consent282721
Withdrew: Other, not specified221

Outcome measures

PrimaryChange From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score

The PANSS measures symptom severity of participants with schizophrenia and contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale with a total minimum score of 30 and a maximum score of 210. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.

Time frame:
Baseline through Week 6
Reported as:
Least squares mean · units on a scale
Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score
units on a scalePlaceboEmraclidine 10 mg, Once Daily (QD)Emraclidine 30 mg, Once Daily (QD)
Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score-13.5 (-17.0 to -10.0)-14.7 (-18.1 to -11.2)-16.5 (-20.0 to -13.1)
Statistical analysis
  • Placebo vs Emraclidine 30 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.1765 · Ls mean difference: -3.0 · 95% CI -7.5 to 1.4Emraclidine 30 mg - Placebo
  • Placebo vs Emraclidine 10 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.6007 · Ls mean difference: -1.2 · 95% CI -5.6 to 3.3Emraclidine 10 mg - Placebo
SecondaryChange From Baseline at Week 6 in the Clinical Global Impression - Severity (CGI-S Score)

The CGI-S captures clinician's response to: "Considering your total clinical experience, how mentally ill is the participant at this time?" The clinician's answer was based on the following scale: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. Negative changes from Baseline indicate less mental illness.

Time frame:
Baseline through Week 6
Reported as:
Least squares mean · units on a scale
Change From Baseline at Week 6 in the Clinical Global Impression - Severity (CGI-S Score)
units on a scalePlaceboEmraclidine 10 mg, Once Daily (QD)Emraclidine 30 mg, Once Daily (QD)
Change From Baseline at Week 6 in the Clinical Global Impression - Severity (CGI-S Score)-0.70 (-0.89 to -0.51)-0.75 (-0.94 to -0.56)-0.84 (-1.03 to -0.65)
Statistical analysis
  • Placebo vs Emraclidine 30 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.2534 · Ls mean difference: -0.14 · 95% CI -0.39 to 0.10Emraclidine 30 mg - Placebo
  • Placebo vs Emraclidine 10 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.6774 · Ls mean difference: -0.05 · 95% CI -0.30 to 0.19Emraclidine 10 mg - Placebo
SecondaryChange From Baseline at All Time Points in Positive and Negative Syndrome Scale (PANSS) Total Score

The PANSS measures symptom severity of participants with schizophrenia and contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale with a total minimum score of 30 and a maximum score of 210. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.

Time frame:
Baseline; Weeks 1, 2, 3, 4, 5, and 6
Reported as:
Least squares mean · units on a scale
Change From Baseline at All Time Points in Positive and Negative Syndrome Scale (PANSS) Total Score
units on a scalePlaceboEmraclidine 10 mg, Once Daily (QD)Emraclidine 30 mg, Once Daily (QD)
Week 1-5.2 (-7.3 to -3.0)-5.7 (-7.8 to -3.6)-6.2 (-8.3 to -4.1)
Week 2-8.7 (-11.3 to -6.1)-8.8 (-11.4 to -6.3)-9.0 (-11.6 to -6.5)
Week 3-10.3 (-13.1 to -7.5)-10.0 (-12.8 to -7.2)-11.3 (-14.1 to -8.6)
Week 4-12.1 (-15.3 to -9.0)-12.8 (-15.9 to -9.6)-13.3 (-16.4 to -10.2)
Week 5-13.2 (-16.5 to -9.9)-14.0 (-17.3 to -10.7)-14.7 (-18.0 to -11.4)
Week 6-13.5 (-17.0 to -10.0)-14.7 (-18.1 to -11.2)-16.5 (-20.0 to -13.1)
Statistical analysis
  • Placebo vs Emraclidine 30 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.3596 · Ls mean difference: -1.0 · 95% CI -3.2 to 1.2Emraclidine 30 mg - Placebo
  • Placebo vs Emraclidine 10 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.6053 · Ls mean difference: -0.6 · 95% CI -2.7 to 1.6Emraclidine 10 mg - Placebo
  • Placebo vs Emraclidine 30 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.8149 · Ls mean difference: -0.4 · 95% CI -3.4 to 2.7Emraclidine 30 mg - Placebo
  • Placebo vs Emraclidine 10 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.9058 · Ls mean difference: -0.2 · 95% CI -3.2 to 2.9Emraclidine 10 mg - Placebo
  • Placebo vs Emraclidine 30 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.5419 · Ls mean difference: -1.0 · 95% CI -4.4 to 2.3Emraclidine 30 mg - Placebo
  • Placebo vs Emraclidine 10 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.8585 · Ls mean difference: 0.3 · 95% CI -3.1 to 3.7Emraclidine 10 mg - Placebo
  • Placebo vs Emraclidine 30 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.5521 · Ls mean difference: -1.2 · 95% CI -5.1 to 2.7Emraclidine 30 mg - Placebo
  • Placebo vs Emraclidine 10 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.7540 · Ls mean difference: -0.6 · 95% CI -4.6 to 3.3Emraclidine 10 mg - Placebo
  • Placebo vs Emraclidine 30 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.4842 · Ls mean difference: -1.5 · 95% CI -5.7 to 2.7Emraclidine 30 mg - Placebo
  • Placebo vs Emraclidine 10 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.6999 · Ls mean difference: -0.8 · 95% CI -5.0 to 3.4Emraclidine 10 mg - Placebo
  • Placebo vs Emraclidine 30 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.1765 · Ls mean difference: -3.0 · 95% CI -7.5 to 1.4Emraclidine 30 mg - Placebo
  • Placebo vs Emraclidine 10 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.6007 · Ls mean difference: -1.2 · 95% CI -5.6 to 3.3Emraclidine 10 mg - Placebo
SecondaryChange From Baseline at All Time Points in the Clinical Global Impression - Severity (CGI-S) Score

The CGI-S captures clinician's response to: "Considering your total clinical experience, how mentally ill is the participant at this time?" The clinician's answer was based on the following scale: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. Negative changes from Baseline indicate less mental illness.

Time frame:
Baseline; Weeks 1, 2, 3, 4, 5, and 6
Reported as:
Least squares mean · units on a scale
Change From Baseline at All Time Points in the Clinical Global Impression - Severity (CGI-S) Score
units on a scalePlaceboEmraclidine 10 mg, Once Daily (QD)Emraclidine 30 mg, Once Daily (QD)
Week 1-0.18 (-0.29 to -0.06)-0.17 (-0.29 to -0.05)-0.21 (-0.32 to -0.09)
Week 2-0.36 (-0.50 to -0.21)-0.39 (-0.54 to -0.25)-0.35 (-0.50 to -0.21)
Week 3-0.48 (-0.64 to -0.32)-0.42 (-0.58 to -0.26)-0.52 (-0.67 to -0.36)
Week 4-0.54 (-0.71 to -0.36)-0.53 (-0.70 to -0.36)-0.70 (-0.87 to -0.53)
Week 5-0.67 (-0.85 to -0.49)-0.64 (-0.82 to -0.46)-0.74 (-0.92 to -0.56)
Week 6-0.70 (-0.89 to -0.51)-0.75 (-0.94 to -0.56)-0.84 (-1.03 to -0.65)
Statistical analysis
  • Placebo vs Emraclidine 30 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.5822 · Ls mean difference: -0.03 · 95% CI -0.15 to 0.09Emraclidine 30 mg - Placebo
  • Placebo vs Emraclidine 10 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.9244 · Ls mean difference: 0.01 · 95% CI -0.11 to 0.13Emraclidine 10 mg - Placebo
  • Placebo vs Emraclidine 30 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.9348 · Ls mean difference: 0.01 · 95% CI -0.17 to 0.18Emraclidine 30 mg - Placebo
  • Placebo vs Emraclidine 10 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.7160 · Ls mean difference: -0.03 · 95% CI -0.21 to 0.14Emraclidine 10 mg - Placebo
  • Placebo vs Emraclidine 30 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.6883 · Ls mean difference: -0.04 · 95% CI -0.24 to 0.16Emraclidine 30 mg - Placebo
  • Placebo vs Emraclidine 10 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.5973 · Ls mean difference: 0.05 · 95% CI -0.14 to 0.25Emraclidine 10 mg - Placebo
  • Placebo vs Emraclidine 30 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.1392 · Ls mean difference: -0.16 · 95% CI -0.38 to 0.05Emraclidine 30 mg - Placebo
  • Placebo vs Emraclidine 10 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.9421 · Ls mean difference: 0.01 · 95% CI -0.21 to 0.23Emraclidine 10 mg - Placebo
  • Placebo vs Emraclidine 30 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.5431 · Ls mean difference: -0.07 · 95% CI -0.30 to 0.16Emraclidine 30 mg - Placebo
  • Placebo vs Emraclidine 10 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.8160 · Ls mean difference: 0.03 · 95% CI -0.20 to 0.26Emraclidine 10 mg - Placebo
  • Placebo vs Emraclidine 30 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.2534 · Ls mean difference: -0.14 · 95% CI -0.39 to 0.10Emraclidine 30 mg - Placebo
  • Placebo vs Emraclidine 10 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.6774 · Ls mean difference: -0.05 · 95% CI -0.30 to 0.19Emraclidine 10 mg - Placebo
SecondaryPercentage of Responders at Week 6 (Responders Defined as ≥30% Reduction From Baseline in Positive and Negative Syndrome Scale [PANSS] Total Score)

The PANSS measures symptom severity of participants with schizophrenia and contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale with a total minimum score of 30 and a maximum score of 210. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms. A PANSS responder is defined as a participant with at least a 30% decrease in PANSS total score compared to Baseline at Week 6 visit or the early termination visit. If a participant discontinued and did not have an early termination visit, the participant's last assessment was considered.

Time frame:
Baseline through Week 6
Reported as:
Number · percentage of participants
Percentage of Responders at Week 6 (Responders Defined as ≥30% Reduction From Baseline in Positive and Negative Syndrome Scale [PANSS] Total Score)
percentage of participantsPlaceboEmraclidine 10 mg, Once Daily (QD)Emraclidine 30 mg, Once Daily (QD)
Percentage of Responders at Week 6 (Responders Defined as ≥30% Reduction From Baseline in Positive and Negative Syndrome Scale [PANSS] Total Score)10.217.617.3
Statistical analysis
  • Placebo vs Emraclidine 30 mg, Once Daily (QD) · Regression, Logistic · p = =0.0904 · Odds ratio: 1.90 · 95% CI 0.90 to 3.99
  • Placebo vs Emraclidine 10 mg, Once Daily (QD) · Regression, Logistic · p = =0.0756 · Odds ratio: 1.96 · 95% CI 0.93 to 4.13
SecondaryNumber of Participants With Treatment Emergent Adverse Event (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

Time frame:
From first dose of study drug until 28 days following last dose of study drug (up to Week 10)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Event (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
ParticipantsPlaceboEmraclidine 10 mg, Once Daily (QD)Emraclidine 30 mg, Once Daily (QD)
Any TEAE737882
TESAE241
SecondaryNumber of Participants With Clinically Significant Changes in Electrocardiogram (ECGs)

12-lead electrocardiogram (ECG) recordings were obtained after the participant had been supine and at rest for at least 3 minutes.

Time frame:
Baseline; from first dose of study drug up to Week 6
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECGs)
ParticipantsPlaceboEmraclidine 10 mg, Once Daily (QD)Emraclidine 30 mg, Once Daily (QD)
QTcF value > 450 - 480 msec531
QTcF value > 480 - 500 msec000
QTcF value > 500 msec000
QTcF increase from Baseline > 30 - 60 msec1388
QTcF increase from Baseline > 60 msec110
SecondaryNumber of Participants With Clinically Significant Changes in Clinical Laboratory Assessments

Clinical laboratory tests were performed at scheduled study visits, and the investigator recorded any clinically significant changes.

Time frame:
Baseline; from first dose of study drug up to Week 6
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments
ParticipantsPlaceboEmraclidine 10 mg, Once Daily (QD)Emraclidine 30 mg, Once Daily (QD)
Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments344
SecondaryNumber of Participants With Clinically Significant Changes in Vital Sign Measurements

Vital signs were obtained after the participant had been supine and at rest for 3 minutes and included temperature, systolic and diastolic blood pressure, respiratory rate, and heart rate. Participants' body weights were also measured and recorded.

Time frame:
Baseline; from first dose of study drug up to Week 6
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Vital Sign Measurements
ParticipantsPlaceboEmraclidine 10 mg, Once Daily (QD)Emraclidine 30 mg, Once Daily (QD)
Supine Systolic Blood Pressure < 90 mmHg000
Supine Systolic Blood Pressure > 140 mmHg and ≤ 160 mmHg15911
Supine Systolic Blood Pressure > 160 mmHg and ≤ 200 mmHg001
Supine Systolic Blood Pressure > 200 mmHg000
Orthostatic Change in Systolic Blood Pressure ≥ 20 mmHg decrease425
Supine Diastolic Blood Pressure < 50 mmHg000
Supine Diastolic Blood Pressure > 90 mmHg and ≤ 100 mmHg10919
Supine Diastolic Blood Pressure > 100 mmHg and ≤ 120 mmHg003
Supine Diastolic Blood Pressure > 120 mmHg000
Orthostatic Change in Diastolic Blood Pressure ≥ 10 mmHg decrease9714
Supine Heart Rate < 50 bpm100
Supine Heart Rate ≥ 50 bpm and < 60 bpm1766
Supine Heart Rate > 100 bpm and ≤ 120 bpm81824
Supine Heart Rate > 120 bpm003
Temperature < 36 °C135
Temperature > 38 °C100
Respiratory Rate < 12 breaths/min000
Respiratory Rate > 20 breaths/min356
Body Weight ≥ 7% decrease111
Body Weight ≥ 7% increase162414
SecondaryNumber of Participants With Clinically Significant Changes in Physical and Neurological Examination Results

The number of participants with clinically significant changes in physical and neurological examination results was documented.

Time frame:
Baseline; from first dose of study drug up to Week 6
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Physical and Neurological Examination Results
ParticipantsPlaceboEmraclidine 10 mg, Once Daily (QD)Emraclidine 30 mg, Once Daily (QD)
Clinically Significant Changes in Physical Examination113
Clinically Significant Changes in Neurological Examination000
SecondaryNumber of Participants With Suicide-Related Treatment-Emergent Events Assessed Using the Columbia Suicide-Severity Rating Scale (C-SSRS)

The C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent).

Time frame:
Baseline; from first dose of study drug up to Week 6
Reported as:
Count of participants · Participants
Number of Participants With Suicide-Related Treatment-Emergent Events Assessed Using the Columbia Suicide-Severity Rating Scale (C-SSRS)
ParticipantsPlaceboEmraclidine 10 mg, Once Daily (QD)Emraclidine 30 mg, Once Daily (QD)
Treatment-Emergent Suicidal Ideation Compared to Recent History127
Treatment-Emergent Serious Suicidal Ideation Compared to Recent History000
Emergence of Serious Suicidal Ideation Compared to Recent History000
Emergence of Suicidal Behavior Compared to all Prior History000
SecondaryChange From Baseline in Simpson Angus Scale (SAS) Total Score

The SAS consists of a list of 10 symptoms of Parkinsonism. Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms and a score of 4 representing a severe condition. The SAS total score is the sum of the scores for all 10 items. Negative changes from Baseline indicate an improvement in symptoms.

Time frame:
Baseline; Weeks 3 and 6
Reported as:
Least squares mean · units on a scale
Change From Baseline in Simpson Angus Scale (SAS) Total Score
units on a scalePlaceboEmraclidine 10 mg, Once Daily (QD)Emraclidine 30 mg, Once Daily (QD)
Week 30.0 (-0.1 to 0.1)0.0 (0.0 to 0.1)0.1 (0.0 to 0.2)
Week 60.0 (-0.1 to 0.1)0.0 (-0.1 to 0.1)0.0 (-0.1 to 0.1)
Statistical analysis
  • Placebo vs Emraclidine 30 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.2418 · Ls mean difference: 0.1 · 95% CI 0.0 to 0.2Emraclidine 30 mg - Placebo
  • Placebo vs Emraclidine 10 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.5720 · Ls mean difference: 0.0 · 95% CI -0.1 to 0.1Emraclidine 10 mg - Placebo
  • Placebo vs Emraclidine 30 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.7459 · Ls mean difference: 0.0 · 95% CI -0.1 to 0.1Emraclidine 30 mg - Placebo
  • Placebo vs Emraclidine 10 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.6729 · Ls mean difference: 0.0 · 95% CI -0.1 to 0.1Emraclidine 10 mg - Placebo
SecondaryChange From Baseline in Abnormal Involuntary Movement Scale (AIMS) Movement Rating Score

The Abnormal Involuntary Movement Scale assessment consists of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1-4), extremity movements (items 5 and 6), and trunk movements (item 7) are observed unobtrusively while the participant is at rest, and the investigator also makes global judgments on the participant's dyskinesias (items 8-10). Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms (for item 10, no awareness), and a score of 4 indicating a severe condition (for item 10, awareness, severe distress). In addition, the AIMS includes 2 yes/no questions that address the participant's dental status. The AIMS Movement Rating Score is defined as the sum of individual scores from items 1-7, ranging from 0 to 28. A lower score indicates less severe or absent abnormal movements. A negative change in the mean from Baseline indicates improvement in the severity of abnormal involuntary movements.

Time frame:
Baseline; Weeks 3 and 6
Reported as:
Least squares mean · units on a scale
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Movement Rating Score
units on a scalePlaceboEmraclidine 10 mg, Once Daily (QD)Emraclidine 30 mg, Once Daily (QD)
Week 30.0 (-0.1 to 0.1)-0.1 (-0.2 to 0.0)0.1 (0.0 to 0.2)
Week 60.0 (-0.1 to 0.1)0.0 (-0.1 to 0.1)0.0 (-0.1 to 0.1)
Statistical analysis
  • Placebo vs Emraclidine 30 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.3783 · Ls mean difference: 0.1 · 95% CI -0.1 to 0.2Emraclidine 30 mg - Placebo
  • Placebo vs Emraclidine 10 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.2242 · Ls mean difference: -0.1 · 95% CI -0.2 to 0.0Emraclidine 10 mg - Placebo
  • Placebo vs Emraclidine 30 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.8626 · Ls mean difference: 0.0 · 95% CI -0.1 to 0.1Emraclidine 30 mg - Placebo
  • Placebo vs Emraclidine 10 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.6106 · Ls mean difference: 0.0 · 95% CI -0.1 to 0.1Emraclidine 10 mg - Placebo
SecondaryChange From Baseline in Barnes Akathisia Rating Scale (BARS) Global Clinical Evaluation Score

The BARS consists of 4 items related to akathisia: The first 3 items are rated on a 4-point scale, with a score of 0 representing absence of symptoms and a score of 3 representing a severe condition. The global clinical evaluation is made on a 6-point scale, with a score of 0 representing absence of symptom and a score of 5 representing severe akathisia. Negative changes from Baseline indicate an improvement in symptoms.

Time frame:
Baseline; Weeks 3 and 6
Reported as:
Least squares mean · units on a scale
Change From Baseline in Barnes Akathisia Rating Scale (BARS) Global Clinical Evaluation Score
units on a scalePlaceboEmraclidine 10 mg, Once Daily (QD)Emraclidine 30 mg, Once Daily (QD)
Week 30.0 (-0.1 to 0.0)0.0 (0.0 to 0.1)0.0 (0.0 to 0.1)
Week 60.0 (0.0 to 0.0)0.0 (-0.1 to 0.0)0.0 (0.0 to 0.0)
Statistical analysis
  • Placebo vs Emraclidine 30 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.4219 · Ls mean difference: 0.0 · 95% CI 0.0 to 0.1Emraclidine 30 mg - Placebo
  • Placebo vs Emraclidine 10 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.3933 · Ls mean difference: 0.0 · 95% CI 0.0 to 0.1Emraclidine 10 mg - Placebo
  • Placebo vs Emraclidine 30 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.7366 · Ls mean difference: 0.0 · 95% CI 0.0 to 0.0Emraclidine 30 mg - Placebo
  • Placebo vs Emraclidine 10 mg, Once Daily (QD) · Mixed Model for Repeated Measures (MMRM) · p = =0.4639 · Ls mean difference: 0.0 · 95% CI -0.1 to 0.0Emraclidine 10 mg - Placebo

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from the time informed consent was signed to the end of the study. The median time on follow-up was 81.5 days for the Placebo group, 77 days for the Emraclidine 10 mg group, and 80 days for the Emraclidine 30 mg group.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/128 (0%)2/128 (1.6%)56/128 (43.8%)
Emraclidine 10 mg, Once Daily (QD)0/128 (0%)4/128 (3.1%)66/128 (51.6%)
Emraclidine 30 mg, Once Daily (QD)0/129 (0%)1/129 (0.8%)74/129 (57.4%)
Most frequent serious events
Most frequent serious events
EventPlaceboEmraclidine 10 mg, Once Daily (QD)Emraclidine 30 mg, Once Daily (QD)
SCHIZOPHRENIAPsychiatric disorders2/1282/1280/129
DYSTONIANervous system disorders0/1281/1280/129
AGITATIONPsychiatric disorders0/1281/1280/129
AGGRESSIONPsychiatric disorders0/1280/1281/129
Most frequent other events
Showing 10 of 26
Most frequent other events
EventPlaceboEmraclidine 10 mg, Once Daily (QD)Emraclidine 30 mg, Once Daily (QD)
WEIGHT INCREASEDInvestigations11/12822/1288/129
HEADACHENervous system disorders12/12818/12817/129
DRY MOUTHGastrointestinal disorders3/1285/12812/129
DYSPEPSIAGastrointestinal disorders4/1285/12810/129
SOMNOLENCENervous system disorders6/1289/1289/129
BACK PAINMusculoskeletal and connective tissue disorders3/1281/1288/129
INSOMNIAPsychiatric disorders5/1286/1283/129
SINUS TACHYCARDIACardiac disorders1/1282/1286/129
NAUSEAGastrointestinal disorders2/1283/1286/129
FATIGUEGeneral disorders1/1280/1285/129

Baseline characteristics

Intent-to-treat (ITT) population: all randomized participants

Age, Continuous
Age, Continuous(years)PlaceboEmraclidine 10 mg, Once Daily (QD)Emraclidine 30 mg, Once Daily (QD)Total
Mean42.9 ± 11.4640.6 ± 11.2842.5 ± 12.2342.0 ± 11.68
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEmraclidine 10 mg, Once Daily (QD)Emraclidine 30 mg, Once Daily (QD)Total
Female31312789
Male9797102296
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboEmraclidine 10 mg, Once Daily (QD)Emraclidine 30 mg, Once Daily (QD)Total
Hispanic or Latino2120950
Not Hispanic or Latino107105118330
Unknown or Not Reported0325
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboEmraclidine 10 mg, Once Daily (QD)Emraclidine 30 mg, Once Daily (QD)Total
American Indian or Alaska Native0033
Asian0022
Native Hawaiian or Other Pacific Islander0011
Black or African American898887264
White373933109
More than one race2136
Unknown or Not Reported0000
08

Study locations

25 sites
  • Little Rock, Arkansas
    Little Rock, Arkansas 72211-3702, United States
  • Anaheim, California
    Anaheim, California 92805-5854, United States
  • Garden Grove, California
    Garden Grove, California 92845-2506, United States
  • Lemon Grove, California
    Lemon Grove, California 91945-2956, United States
  • Montclair, California
    Montclair, California 91763-2231, United States
  • Riverside, California
    Riverside, California 92506-3257, United States
  • San Diego, California
    San Diego, California 92123, United States
  • Hialeah, Florida
    Hialeah, Florida 33012-4648, United States
  • Hollywood, Florida
    Hollywood, Florida 33021-5414, United States
  • Mangonia Park, Florida
    Mangonia Park, Florida 33407-2413, United States
  • Oakland Park, Florida
    Oakland Park, Florida 33334-4135, United States
  • Atlanta, Georgia
    Atlanta, Georgia 30328-4018, United States
  • Decatur, Georgia
    Decatur, Georgia 30030-3438, United States
  • Shreveport, Louisiana
    Shreveport, Louisiana 71101-4603, United States
  • Gaithersburg, Maryland
    Gaithersburg, Maryland 20877-1409, United States
  • Flowood, Mississippi
    Flowood, Mississippi 39232-8016, United States
  • North Canton, Ohio
    North Canton, Ohio 44720, United States
  • DeSoto, Texas
    DeSoto, Texas 75115-2092, United States
  • Houston, Texas
    Houston, Texas 77043-2735, United States
  • Irving, Texas
    Irving, Texas 75062-2323, United States
  • Richardson, Texas
    Richardson, Texas 75080, United States
  • Stara Zagora
    Stara Zagora, 6003, Bulgaria
  • Veliko Tarnovo
    Veliko Tarnovo, 5000, Bulgaria
  • Veliko Tarnovo, Veliko Tarnovo
    Veliko Tarnovo, 5047, Bulgaria
  • Vratsa, Vratsa
    Vratsa, 3000, Bulgaria
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Aug 2024, 25 months.

Results were first posted in Sep 2025, 1 year after primary completion.

Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 25 months is above that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2022
First posted
Feb 7, 2022
StartActual
Jun 30, 2022
Primary completionActual
Aug 23, 2024
CompletionActual
Aug 26, 2024
Results first posted
Sep 17, 2025
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05227690
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 7, 2022
Start date
Jun 30, 2022
Primary completion
Aug 23, 2024
Completion
Aug 26, 2024
Results posted
Sep 17, 2025
Last update
Sep 17, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emraclidine

Start the discussion